29 results on '"Petito V"'
Search Results
2. OC.08.6 IMMUNE AND NON IMMUNE CHANGES FOLLOWING FMT IN EXPERIMENTAL COLITIS: EMERGING PATHWAYS OF FMTDERIVED MUCOSAL HEALING
3. OC.02.5 THE SOLUTE CARRIER LC22A4/OCTN1 AS A NOVEL IBD DETERMINANT AT THE MICROBE-HOST INTERFACE
4. OC.05.5 ALTERATION IN THE ABUNDANCE OF AKKERMANSIA MUCINIPHILA IS ASSOCIATED TO GASTROINTESTINAL AND EXTRA-INTESTINAL DISEASES: TOWARDS THE IDENTIFICATION OF SPECIFIC MICROBIAL SIGNATURES OF DISEASE
5. OC.04.5 IL-33/ST2 LEVELS AND GUT MICROBIOTA CHARACTERIZATION CAN PREDICT MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
6. OC.04.1 MOLECULAR PATHWAYS OF SARCOPENIA IN DSS ACUTE MODEL OF MURINE COLITIS
7. P.07.20 FATIGUE AS A POSSIBLE MARKER OF SARCOPENIA IN INFLAMMATORY BOWEL DISEASE PATIENTS
8. P.07.10 OCULAR MANIFESTATIONS IN A TERTIARY IBD CENTER: BETTER TO KEEP AN EYE ON
9. OC.16.6 EMERGING ROLE OF IL-33/ST2 LEVELS IN PREDICTING MUCOSAL RESPONSE TO ANTI-TNF THERAPY IN ULCERATIVE COLITIS
10. OC.16.1 ALTERATIONS IN CYTOKINE EXPRESSION PROFILE IN COLON MUCOSA OF IBD PATIENTS AND IN RESPONSE TO ANTI-TNF-A TREATMENT
11. OC.12.1 THE IMPACT OF TROPHIC EFFECTS OF MULTI STRAIN PROBIOTIC PREPARATION ON PARACELLULAR PERMEABILITY
12. OC.10.2 ANTI-TNF-ALPHA THERAPY INDUCES MICROBIAL AND IMMUNOLOGICAL CHANGES IN DEXTRAN SODIUM SULPHATE CHRONIC COLITIS
13. P.05.9: Colitis is Associated with Muscle Function Alteration: Emerging Mechanisms of Asthenia in IBD?
14. P.05.8: Clausii in Colitis: Role and Mechanisms of Action of Bacillus Clausii in Experimental Colitis
15. P.03.12: Breath Methane Production in Lactulose Breath Test is Affected by Gender, a Post HOC Italian Study
16. OC.14.6: Escherichia Coli Nissle 1917 Modulate GUT Microbiota Composition in Ulcerative Colitis Patients
17. P.09.15 INCREASED ABUNDANCE OF BENEFICIAL BACTERIA IS ASSOCIATED WITH CLINICAL IMPROVEMENT AFTER RIFAXIMIN TREATMENT
18. P.07.1 GUT MICROBIOTA MOLECULAR SPECTRUM IN HEALTHY CONTROLS, DIVERTICULAR DISEASE, IBS AND IBD PATIENTS: TIME FOR MICROBIAL MARKER OF GASTROINTESTINAL DISORDERS?
19. P.01.9 THE GUT MICROBIOTA OF CIRRHOTIC PATIENTS WITH POOR NUTRITIONAL STATUS: PRELIMINARY EVIDENCES
20. The gut microbiota of cirrhotic patients with poor nutritional status: Preliminary evidences
21. First steps towards understanding the dynamic evolution of gut microbiota in different stages of liver disease
22. P.06.9 INFLIXIMAB IS NOT INCREASING COLONIC CANCER RISK ASSOCIATED TO CHRONIC COLITIS IN MICE
23. OC.16.4 DIRECT ROLE OF INFLIXIMAB ON INTESTINAL MUCOSA SUSTAINS MUCOSAL HEALING: EXPLORING NEW MECHANISMS OF ACTION
24. P.03.1 INFLIXIMAB (IFX) ACTS LOCALLY ON INTESTINAL MUCOSA AND ITS PHARMACOKINETIC IS DIFFERENT IN DSS COLITIC MICE COMPARED TO CONTROLS
25. OC.07.6 GELENTERUM AMELIORATES SEVERITY OF COLITIS IN DSS MURINE MODEL, WHILE MODULATING GUT MICROBIOTA AND INTESTINAL MUCUS LAYER
26. P.16.1 INFLIXIMAB AND TNF ALFA MEASUREMENT IN INTESTINAL MUCOSA OF IBD PATIENTS: A NEW TOOL FOR THE CLINIC?
27. P.06.5 DIRECT EFFECTS OF INFLIXIMAB (IFX) ON INTESTINAL MUCOSA: EXPLORING MECHANISMS OF MUCOSAL HEALING
28. P.1.202: TANAGEL REDUCES COLITIS SEVERITY IN DEXTRAN SODIUM SULPHATE (DSS) MODEL OF MURINE ACUTE COLITIS
29. P.1.188: EFFECTS OF INFLIXIMAB (IFX) ON INTESTINAL EPITHELIAL CELLS: EXPLORING MECHANISMS OF MUCOSAL HEALING
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.